MedPath

Opioid Rapid Response System: Naloxone Training in Communities

Not Applicable
Recruiting
Conditions
Opioid Overdose
Interventions
Behavioral: Non-active opioid overdose response training
Behavioral: Opioid Rapid Resonse System (ORRS) training
Registration Number
NCT06238128
Lead Sponsor
University of Missouri-Columbia
Brief Summary

The pervasive impact of the opioid epidemic has touched all layers of society for the past two decades, resulting in over 115 deaths daily and imposing annual costs of $78.5 billion. Responding swiftly to overdoses, akin to various medical emergencies, poses a significant challenge, particularly in geographically dispersed rural areas and densely populated urban settings. Effectively delivering the life-saving drug naloxone, which counteracts the effects of overdoses, necessitates a well-coordinated and cost-efficient response system.

Simply opting for widespread distribution of naloxone, even with citizen involvement, proves to be a financially burdensome approach when compared to more targeted strategies. Moreover, obstacles such as limited access, inadequate or unavailable naloxone training, and delayed response times from emergency responders compound the problem. Addressing these issues, the proposed Opioid Rapid Response System (ORRS) project seeks to advance prevention science by adopting an innovative approach that incorporates technology and contemporary communication theory.

The primary objective of the ORRS project is to mitigate opioid overdose deaths by enlisting and training citizens to administer naloxone in response to such events. Leveraging the PulsePoint health app, which connects citizens to cardiac events, the ORRS project will extend its capabilities to respond to overdose incidents. This initiative involves comprehensive development of ORRS, followed by a randomized clinical trial on a national scale to assess its effectiveness. The study aims to contribute to both prevention and implementation science by identifying optimal recruitment strategies and testing a model of online training. In pursuit of these objectives, the study is guided by the following Specific Aims:

SA 1: Refine and complete the development of ORRS. SA 2: Conduct a randomized clinical trial to evaluate the effectiveness of the intervention. SA 3: Prepare ORRS for dissemination.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1600
Inclusion Criteria
  • Citizens who live in participating PulsePoint communities
  • Must to be 18 and older
  • Must be fluent in English
  • Must have access to the mobile data and able to download and use apps in a smartphone
Exclusion Criteria
  • Citizens who do not live in participating PulsePoint communities
  • Under 18-year-old
  • Citizens who are not fluent in English
  • Citizens who do not have access to mobile data and unable to download and use apps in a smartphone.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Waitlist groupNon-active opioid overdose response trainingParticipants will receive non-active opioid overdose response training. Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training. Once the project is completed, participants will receive online Naloxone training.
ORRS training groupOpioid Rapid Resonse System (ORRS) trainingOnline Naloxone training
Primary Outcome Measures
NameTimeMethod
Number of Participants to response to overdose events from PulsePoint app.Up to 6 months

Single item: whether participant response to overdose events from PulsePoint notifications/alerts

Knowledge of overdose managementup to 24 hours

Investigators will use a subset of Opioid Overdose Knowledge Scale (OOKS) to measure through a forced choice scale with each choice coded as correct (=1) or incorrect (=0). Higher score indicated greater knowledge of overdose management.

Response efficacy about intervening opioid overdoseup to 24 hours

Investigators will develop and measure how participants perceive the effectiveness of activities to intervene opioid overdose events in communities. Response options are from 0 (not effective) to 100 (highly effective). Higher score indicate greater response efficacy.

Knowledge of overdose signup to 24 hours

Investigators will use a subset of Opioid Overdose Knowledge Scale (OOKS) to measure through a forced choice scale with each choice coded as correct (=1) or incorrect (=0). Higher score indicated greater knowledge of overdose sign.

Self-Efficacy toward intervening opioid overdoseup to 24 hours

Investigators will modify self-efficacy scale developed and theorized by Bandura (2005). Response options are from 0 (no confident) to 100 (highly confident). Higher score indicates greater self-efficacy

Concerns related to overdose managementup to 24 hours

Investigators will use a subset of Opioid Overdose Attitude Scale (OOAS) with 5 point scale (1: strongly disagree \~5: strongly agree). Higher score indicates the greater concerns.

Intent to intervene opioid overdose events in communitiesup to 1 month

Investigators will use behavioral intention scale developed by in the opioid training literature (Hecht et al., 2023) to measure intent to intervene opioid overdose events in communities (e.g., administering Narcan). Response options are from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicates grater intention to intervene opioid overdose events in communities.

The number of days per week, on average, to carry NarcanUp to 6 months

Single item: how many days per week, on average, participants carry Narcn

Number of participants to administer NarcanUp to 6 months

Single item: Whether participant administer Narcan to respond opioid overdose events in communities.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ewald & Wasserman Research Consultants, LLC

🇺🇸

San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath